🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
ResMed Inc. (RMD)
NYSE: RMD · Real-Time Price · USD
242.61
+4.76 (2.00%)
At close: Nov 18, 2026, 4:00 PM EST
242.73
+0.12 (0.05%)
After-hours: Nov 18, 2026, 7:54 PM EST
← View all transcripts

AGM 2026

Nov 18, 2026

Summary

Stockholders elected all 10 director nominees, ratified PwC, and approved executive compensation. The update highlighted Q1 growth, capital returns, digital health expansion, and a 2030 goal of changing 500 million lives.

Mike Rider
Global General Counsel and Secretary, ResMed

Good afternoon and good morning, ladies and gentlemen. Thank you for joining us today. My name is Mike Rider, ResMed's Global General Counsel and Secretary. Welcome to ResMed's 2026 Annual Stockholders Meeting. To provide expanded stockholder access and participation, we are once again conducting our annual meeting in a virtual-only format. During the meeting, the online polls will be open for voting by anyone who has registered on the portal and wishes to vote online with respect to any of the three proposals. Instructions for online registration can be found in your proxy materials.

While the meeting is virtual only, we welcome questions from our stockholders. We will answer questions from stockholders who have registered via the virtual meeting portal. If you are registered on the portal, you will have opportunities to ask questions related to the proposals when each specific proposal is taken up. Each stockholder is limited to two questions. If you have difficulty registering, please email us at investorrelations@resmed.com. We have a team standing by that can help you. We will close the polls at the end of the discussion of our three proposals. We will also have a general question-and-answer portion of the meeting where other questions can be asked.

I'd like to call your attention to the rules of conduct for the meeting. They can be found at the link located at the bottom of the virtual annual meeting screen. I will now turn the meeting over to our host, Mr. Mick Farrell.

Mick Farrell
Chairman and CEO, ResMed

Good morning and good afternoon, ladies and gentlemen, and welcome to ResMed's Annual General Meeting. My name is Mick Farrell. I'm the Chairman and Chief Executive Officer of ResMed. Before we begin, I'd like to take a moment to introduce our directors and officers, who are with me here in the room and on the line for this virtual meeting today. Let me start with my fellow continuing directors who are present with us.

Carol Burt is our Lead Director. She's Chair of our Nominating and Governance Committee and member of our Audit Committee, as well as member of our Compliance, Privacy, and Quality Committee. Second, Chris DelOrefice, who is Chair of our Audit Committee. Third, Jan De Witte, who is a member of our Audit Committee, is also a member of our Compensation and Leadership Development Committee, and also a member of our Nominating and Governance Committee. Fourth is Karen Drexler, who is Chair of our Compensation and Leadership Development Committee, and a member of our Nominating and Governance Committee, and a member of our Compliance, Privacy, and Quality Committee. Fifth is Harjit Gill, who is Chair of the Compliance, Privacy, and Quality Committee, and a member of our Compensation and Leadership Development Committee, and a member of our Audit Committee.

Next is John Hernandez, who is a member of our Audit Committee and a member of our Compliance, Privacy, and Quality Committee. Next is Nicole Mowad-Nassar, who is a member of our Compliance, Privacy, and Quality Committee. Next is Desney Tan, who is a member of our Compensation and Leadership Development Committee, as well as a member of our Nominating and Governance Committee. And finally, Peter Farrell, who is our Founder and Chairman Emeritus, and is not a member of any committees.

Next, let me introduce two other ResMed officers who are present with me here and available on the speaker's line today. To my left is Mike Rider, our Global General Counsel and Corporate Secretary, and across the table from me is Aaron Bloomer, our Chief Financial Officer. Continuing with the introductions of our auditor, Lindsey Piziali from PricewaterhouseCoopers, or PwC. They are ResMed's independent registered public accounting firm, and they are available on the speaker's line. For the administration of this meeting, Mike Rider will act as secretary, and Jim Alden from American Election Services will act as the inspector of elections.

I will now call the meeting to order. The 2026 Annual General Meeting of Stockholders of ResMed Inc. will now come to order. We will begin with the formal part of the meeting, which consists of items one to three on the agenda circulated in the notice of meeting and proxy statement. After the formal part of the meeting, I will open the virtual meeting to general questions. We will announce the preliminary results of the voting before the end of the meeting, after all the items have been voted on. I will now ask Mr. Rider to report on the mailing of the notice of the meeting and the notice and access to proxy materials, and also to advise if there is a quorum present so that we may begin our AGM.

Mike Rider
Global General Counsel and Secretary, ResMed

Mr. Farrell, the notice of internet availability of proxy materials for the meeting was mailed on or about October 1st, 2026, to all stockholders of record as of September 22nd, 2026. Represented at this meeting, in person, online, or by proxy, are 112,860,360 shares of common stock, representing approximately 80.24% of the shares outstanding and entitled to a vote.

Mick Farrell
Chairman and CEO, ResMed

Thank you, Mike. A quorum is therefore present, and we may now carry out the official business of this meeting. The time is now 10:06 A.M. Australian Eastern Time, and the polls are now open for each matter to be voted on today.

The first item of business is the election of 10 directors. The board of directors has nominated Carol Burt, Jan De Witte, Chris DelOrefice, Karen Drexler, Michael Farrell, Peter Farrell, Harjit Gill, John Hernandez, Nicole Mowad-Nassar, and Desney Tan to serve as directors of ResMed until the 2027 Annual General Meeting. Because no other persons have been properly nominated in accordance with the bylaws of ResMed, the nominations are now closed. Is there any discussion with respect to the nomination of directors?

Mike Rider
Global General Counsel and Secretary, ResMed

Mr. Chairman, no questions have been submitted.

Mick Farrell
Chairman and CEO, ResMed

Thank you. The second item of business is to ratify the appointment of PricewaterhouseCoopers as ResMed's independent registered public accounting firm for the fiscal year ending June 30, 2027. Mike, is there any discussion or questions about PwC's appointment?

Mike Rider
Global General Counsel and Secretary, ResMed

No questions have been submitted.

Mick Farrell
Chairman and CEO, ResMed

Thank you. The third item of business is to approve, on an advisory basis, the compensation paid to our named executive officers, as disclosed in the proxy statement. Are there any questions or discussion on this topic, Mike?

Mike Rider
Global General Counsel and Secretary, ResMed

No questions have been submitted.

Mick Farrell
Chairman and CEO, ResMed

Thank you. These are the only proposals for today's meeting. The time is currently 10:07 A.M. Australian Eastern Daylight Time on November 19th, and the polls are now closed for this meeting. The inspector of elections has completed the preliminary vote tabulation, so will the secretary please report on those voting results?

Mike Rider
Global General Counsel and Secretary, ResMed

Mr. Chairman, the preliminary results are as follows: Carol Burt, Jan De Witte, Christopher DelOrefice, Karen Drexler, Michael Farrell, Peter Farrell, Harjit Gill, John Hernandez, Nicole Mowad-Nassar, and Desney Tan are elected as directors. Second, the appointment of PwC as our independent registered public accounting firm is ratified. Third, the proposal to approve, on an advisory basis, the compensation paid to our named executive officers, as disclosed in the proxy statement, is approved. The final results and voting details will be reported in a filing we will make with the U.S. Securities and Exchange Commission and on the Australian Securities Exchange, and which will be available on our website.

Mick Farrell
Chairman and CEO, ResMed

Thank you, Mike. This concludes the formal portion of the annual general meeting, and I declare the meeting adjourned.

Great. I am going to just do a two or three-minute business update, and then we will open up the floor for questions, any questions from shareholders, and then we will conclude the informal part of the meeting. The team has given me a whole page of great notes, but many of you, our shareholders, have looked at our earnings call and gone through the details, and I will not be providing material public information beyond that. Let me talk about just three things.

Firstly, about our product velocity, resupply, rePAP, and our work in middle-of-funnel demand curation. We have built here at ResMed the world's leading digital health ecosystem in med tech. We have over 29 billion nights of respiratory medical data. We have over 36 million 100% cloud-connectable medical devices sold in over 144 countries worldwide, and we have over 39 million patients in our ecosystem. What's important about that is not just the information and the data, but what we can do with it to unlock value for patients, for physicians, and for providers.

I'll just walk through a couple of examples. Resupply. In the area of resupply, we've recently upgraded myAir to have a feature we call Equipment Care, where patients can see a timeline of how long it is until they need to replace their mask, their tubing, their filters, and other accessories. This is just another way for us to engage with patients and help them understand how to get fresh equipment and perfectly functioning equipment to help them with their respiratory medical needs, their sleep apnea, their insomnia, their COPD, and beyond.

On adherence, some of our recent product velocity work, our fabric masks are showing a 6% higher adherence versus their silicone equivalents. That's our AirTouch N30i that's now been out about 18 months, and our AirTouch F40 that just came out. We hope that that can achieve the same levels of adherence. We're also seeing a once-in-a-generation demand gen opportunity from large pharma companies with their glucagon-like peptide products. They're bringing patients into primary care like never before, and we're seeing that these patients are 11% more likely to start therapy, 3% more likely to resupply at one year, and more than 7% more likely to resupply at three years.

I'll go into now talk a little bit about our momentum around inorganic growth. We acquired a company that has a product called Nidra. This product, Nidra, is for restless legs syndrome, RLS, that could help 400 million people worldwide. It's a non-invasive, drug-free, sleep physician-prescribed, VA and DME channel-delivered product, and we're really excited to bring it to market. It feels like ResMed 1994 with this group of us, just before our IPO into NASDAQ. We don't have to go out and look for capital. We're going to be sponsoring the growth of this, $20 million last year to $34 million this year. We are creating what I will call a new platform in non-invasive nerve stimulation for sleep health, breathing health, and health tech at home.

I'll close with the financials. Our capital return has been incredibly strong, as you saw last quarter. We had Q1 growth of 7% in constant currency core business. We had 50 basis points improvement year-on-year, and we had non-GAAP EPS that was up 14%, double our growth rate of revenue. We've generated incredible free cash flow. We returned over $1 billion in capital, including $936 million from a share buyback and an ASR included in that, as well as our dividend.

I'll close with this. Resmed is a compelling investment opportunity, an incredibly high ROI opportunity when you think about the TAM of 2.7 billion people worldwide between sleep apnea, insomnia, restless legs syndrome, and COPD. But more important than that, we are changing lives every day. We've changed over 162 million lives with a CPAP, an APAP, a bilevel, a mask product, or a digital health product the last 12 months, and we're going to grow that double digits every year through 2030, and our aspiration is to change 500 million lives in the year 2030.

With that, I will close the informal part of our meeting. That concludes my presentation. Are there any questions from shareholders on our online system, Mr. Secretary?

Mike Rider
Global General Counsel and Secretary, ResMed

We have received no questions as of the close of your remarks, Mr. Chairman.

Mick Farrell
Chairman and CEO, ResMed

Fantastic. The time is 10:13 A.M. Australian Eastern Daylight Time, and that concludes our meeting. Thank you all for joining us today. You may now disconnect.

Mike Rider
Global General Counsel and Secretary, ResMed

Thank you. This concludes today's annual meeting. You may now disconnect.